2020 Q1 Form 10-Q Financial Statement
#000156459020019460 Filed on April 29, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $246.2M | $223.1M |
| YoY Change | 10.36% | -0.91% |
| Cost Of Revenue | $47.21M | $45.36M |
| YoY Change | 4.08% | 1.99% |
| Gross Profit | $199.0M | $177.7M |
| YoY Change | 11.97% | -1.62% |
| Gross Profit Margin | 80.83% | 79.67% |
| Selling, General & Admin | $133.4M | $141.2M |
| YoY Change | -5.56% | 19.53% |
| % of Gross Profit | 67.02% | 79.45% |
| Research & Development | $93.28M | $102.6M |
| YoY Change | -9.06% | -5.33% |
| % of Gross Profit | 46.87% | 57.71% |
| Depreciation & Amortization | $20.61M | $19.64M |
| YoY Change | 4.92% | -23.64% |
| % of Gross Profit | 10.36% | 11.05% |
| Operating Expenses | $226.7M | $243.8M |
| YoY Change | -7.03% | 7.64% |
| Operating Profit | -$37.37M | -$76.00M |
| YoY Change | -50.83% | 22.8% |
| Interest Expense | -$100.0K | $3.500M |
| YoY Change | -102.86% | -36.21% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $6.045M | -$24.25M |
| YoY Change | -124.93% | 374.58% |
| Pretax Income | -$31.33M | -$100.3M |
| YoY Change | -68.75% | 49.63% |
| Income Tax | $7.300M | -$3.854M |
| % Of Pretax Income | ||
| Net Earnings | -$38.65M | -$96.40M |
| YoY Change | -59.9% | 54.22% |
| Net Earnings / Revenue | -15.7% | -43.21% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$244.8K | -$616.8K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 157.8M | 156.0M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $496.0M | $582.1M |
| YoY Change | -14.79% | 43.87% |
| Cash & Equivalents | $176.1M | $225.2M |
| Short-Term Investments | $319.9M | $356.9M |
| Other Short-Term Assets | $46.40M | $56.50M |
| YoY Change | -17.88% | 21.51% |
| Inventory | $109.3M | $92.90M |
| Prepaid Expenses | ||
| Receivables | $260.9M | $231.3M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $912.6M | $962.7M |
| YoY Change | -5.2% | 24.04% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $362.5M | $320.0M |
| YoY Change | 13.29% | 10.5% |
| Goodwill | $92.87M | $92.87M |
| YoY Change | 0.0% | |
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $53.70M | $48.60M |
| YoY Change | 10.49% | -65.65% |
| Other Assets | $148.7M | $133.3M |
| YoY Change | 11.55% | -32.13% |
| Total Long-Term Assets | $913.3M | $793.8M |
| YoY Change | 15.05% | -17.36% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $912.6M | $962.7M |
| Total Long-Term Assets | $913.3M | $793.8M |
| Total Assets | $1.826B | $1.757B |
| YoY Change | 3.95% | 1.15% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $43.18M | $48.96M |
| YoY Change | -11.8% | -25.14% |
| Accrued Expenses | $287.0M | $273.8M |
| YoY Change | 4.82% | 35.08% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $2.800M | $2.843M |
| YoY Change | -1.51% | 1.54% |
| Total Short-Term Liabilities | $339.8M | $327.7M |
| YoY Change | 3.7% | 19.38% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $273.8M | $275.9M |
| YoY Change | -0.77% | -0.78% |
| Other Long-Term Liabilities | $149.3M | $28.43M |
| YoY Change | 425.24% | 1.52% |
| Total Long-Term Liabilities | $423.1M | $304.3M |
| YoY Change | 39.02% | -0.57% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $339.8M | $327.7M |
| Total Long-Term Liabilities | $423.1M | $304.3M |
| Total Liabilities | $762.9M | $654.4M |
| YoY Change | 16.58% | 12.69% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.282B | |
| YoY Change | -142518.44% | |
| Common Stock | $2.504B | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $1.063B | $1.102B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $1.826B | $1.757B |
| YoY Change | 3.95% | 1.15% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$38.65M | -$96.40M |
| YoY Change | -59.9% | 54.22% |
| Depreciation, Depletion And Amortization | $20.61M | $19.64M |
| YoY Change | 4.92% | -23.64% |
| Cash From Operating Activities | -$40.27M | $22.21M |
| YoY Change | -281.31% | -182.76% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $19.80M | $23.64M |
| YoY Change | -16.24% | 27.88% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $37.30M | -$41.10M |
| YoY Change | -190.75% | -193.84% |
| Cash From Investing Activities | $17.49M | -$64.70M |
| YoY Change | -127.03% | -355.3% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | $711.0K | $711.0K |
| YoY Change | 0.0% | |
| Cash From Financing Activities | -4.924M | 963.0K |
| YoY Change | -611.32% | -129.21% |
| NET CHANGE | ||
| Cash From Operating Activities | -40.27M | 22.21M |
| Cash From Investing Activities | 17.49M | -64.70M |
| Cash From Financing Activities | -4.924M | 963.0K |
| Net Change In Cash | -27.70M | -41.53M |
| YoY Change | -33.29% | 766.79% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$40.27M | $22.21M |
| Capital Expenditures | $19.80M | $23.64M |
| Free Cash Flow | -$60.07M | -$1.427M |
| YoY Change | 4109.6% | -96.85% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q1 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2020Q1 | us-gaap |
Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
|
92781000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-859000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
725000 | |
| CY2020Q1 | alks |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-2378000 | |
| CY2019Q1 | alks |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-2297000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
48000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
19642000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
19813000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
24616000 | |
| CY2020Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
3665000 | |
| CY2020Q1 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
283000 | |
| CY2019Q1 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
1116000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-10370000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-69411000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
|
5813000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
|
217000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
6842000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1700000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-13615000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
69000 | |
| CY2020Q1 | alks |
Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
|
-3926000 | |
| CY2019Q1 | alks |
Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
|
-2131000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-51254000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-15888000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
1765000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-40272000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
22212000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
19799000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
23639000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
3000 | |
| CY2019Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
85000 | |
| CY2019Q1 | alks |
Proceeds From Contingent Consideration
ProceedsFromContingentConsideration
|
5000000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
27212000 | |
| CY2020Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
|
6800000 | |
| CY2019Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
|
-22600000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-658000 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-31325000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-38654000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.24 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
156336000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-38654000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
87000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
317000 | |
| CY2019Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
45361000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
102570000 | |
| CY2019Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
141220000 | |
| CY2019Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9952000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-76001000 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1721000 | |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-24251000 | |
| CY2019Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-100252000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.62 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
158095000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-96398000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
229000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
770000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-38337000 | |
| CY2019Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-3225000 | |
| CY2020Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
|
6800000 | |
| CY2019Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
|
-22600000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
20608000 | |
| CY2019Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
299103000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-95628000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
87000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
|
8333000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
28834000 | |
| CY2019Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
55978000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1085442000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
3071000 | |
| CY2019Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
34353000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
10645000 | |
| CY2020Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
43177000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
368449000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
370126000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
64500000 | |
| CY2019Q1 | alks |
Marketable Securities Realized Loss
MarketableSecuritiesRealizedLoss
|
492000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
223691000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
224692000 | |
| CY2020Q1 | us-gaap |
Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
|
3487000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
144758000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
145434000 | |
| CY2020Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="N1_COMPANY" style="margin-top:10pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. THE COMPANY</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Headquartered in Dublin, Ireland, the Company has a research and development (“R&D”) center in Waltham, Massachusetts; an R&D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. </p> | |
| CY2019Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
102127000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
64500000 | |
| CY2019Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
55978000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
17492000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-64703000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
3070000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
10554000 | |
| CY2020Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
7283000 | |
| CY2019Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
8880000 | |
| CY2020Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
711000 | |
| CY2019Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
711000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-4924000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
963000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-27704000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-41528000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
203771000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
266762000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
176067000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
225234000 | |
| CY2020Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
|
5242000 | |
| CY2019Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
|
7850000 | |
| CY2020Q1 | alks |
Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
|
-7283000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1171285000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
10554000 | |
| CY2019Q1 | alks |
Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
|
-8880000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
24810000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
229000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
770000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-96398000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1102141000 | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies, including those related to revenue from contracts with its customers and related allowances, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments, contingent consideration and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.</p> | |
| CY2020Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2020Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risks and Uncertainties</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, COVID-19 was declared a global pandemic by the World Health Organization. To date, COVID-19 has surfaced in nearly all regions around the world and resulted in travel restrictions and business slowdowns or shutdowns in affected areas. The Company is closely monitoring and rapidly responding to the impact of COVID-19 on its employees, communities and business operations. Due to numerous uncertainties surrounding the COVID-19 pandemic, the Company is unable to predict the extent of the impact that the COVID-19 pandemic may have on the Company’s future financial condition and operating results. These uncertainties include, among other things, the ultimate severity and duration of the pandemic; governmental, business or other actions that have been, or will be, taken in response to the pandemic, including restrictions on travel and mobility, business closures and imposition of social distancing measures; impacts of the pandemic on the vendors or distribution channels in the Company’s supply chain and on the Company’s ability to continue to manufacture its products; impacts of the pandemic on the conduct of the Company’s clinical trials, including with respect to enrollment rates, availability of investigators and clinical trial sites or monitoring of data; impacts of the pandemic on healthcare systems that serve people living with opioid dependence, alcohol dependence and schizophrenia; impacts of the pandemic on the regulatory agencies with which the Company interacts in the development, review, approval and commercialization of its medicines; impacts of the pandemic on reimbursement for the Company’s products, including the Company’s Medicaid rebate liability, and for services related to the use of its products; and impacts of the pandemic on the U.S., Irish and global economies more broadly. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite disruptions to the Company’s business operations and the business operations of third parties on which it relies, the COVID-19 pandemic did not significantly impact the Company’s operating results and financial condition for the three months ended March 31, 2020. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon third parties for many aspects of our business, including the provision of goods and services related to the manufacture of our clinical products and our, and our partners’, marketed products, the conduct of our clinical trials, and the sale of marketed products from which we receive manufacturing and royalty revenue. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketed products from which the Company derives revenue, including manufacturing and royalty revenue, are primarily injectable medications administered by healthcare professionals, and given developments that have transpired to date, and may continue to transpire, in response to the pandemic, including the implementation of “shelter-in-place” policies, social distancing and other measures, the Company expects commercial sales of these marketed products to be adversely impacted. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As it relates to its proprietary marketed products, VIVITROL and ARISTADA, the Company has begun to see commercial impacts of the COVID-19 pandemic in the second quarter. As of the date of this Form 10-Q, April VIVITROL shipments are down from pre-COVID-19 expectations, and the Company has seen a flattening in prescription data and factory shipments of ARISTADA. The Company is actively working to respond to these developments, including by working to increase the number of providers able to administer these products and otherwise support uninterrupted access to these products. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to operate its manufacturing facilities and supply its medicines, and it does not currently anticipate any supply interruptions. While the Company continues to conduct R&D activities, including its ongoing clinical trials, the COVID-19 pandemic has impacted, and may continue to impact, the timelines of certain of its early-stage discovery efforts and clinical trials. The Company is working with its internal teams, its clinical investigators, R&D vendors and critical supply chain vendors, to continually assess, and mitigate, the potential impact of COVID-19 on its manufacturing operations and R&D activities.</p> | |
| CY2020Q1 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
14200000 | |
| CY2020Q1 | alks |
Consideration Expects To Receive Period
ConsiderationExpectsToReceivePeriod
|
P3Y | |
| CY2019Q4 | alks |
Contract With Customer Assets
ContractWithCustomerAssets
|
13386000 | |
| CY2020Q1 | alks |
Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
|
14146000 | |
| CY2020Q1 | alks |
Contract With Customer Assets
ContractWithCustomerAssets
|
19199000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
-859000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
27975000 | |
| CY2020Q1 | alks |
Short Term Investment Amortized Cost
ShortTermInvestmentAmortizedCost
|
317539000 | |
| CY2020Q1 | alks |
Short Term Investment Securities Unrealized Gain Loss
ShortTermInvestmentSecuritiesUnrealizedGainLoss
|
2659000 | |
| CY2020Q1 | alks |
Short Term Investment Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
ShortTermInvestmentSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
|
270000 | |
| CY2020Q1 | alks |
Short Term Investment Securities Continuous Unrealized Loss Position More Than12 Months Aggregate Losses
ShortTermInvestmentSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAggregateLosses
|
1000 | |
| CY2020Q1 | us-gaap |
Short Term Investments
ShortTermInvestments
|
319927000 | |
| CY2020Q1 | alks |
Long Term Investment Amortized Cost
LongTermInvestmentAmortizedCost
|
54397000 | |
| CY2020Q1 | alks |
Long Term Investment Securities Unrealized Gain Loss
LongTermInvestmentSecuritiesUnrealizedGainLoss
|
58000 | |
| CY2020Q1 | alks |
Long Term Investment Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
|
710000 | |
| CY2020Q1 | alks |
Long Term Investment Securities Continuous Unrealized Loss Position More Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAggregateLosses
|
1000 | |
| CY2020Q1 | us-gaap |
Long Term Investments
LongTermInvestments
|
53744000 | |
| CY2020Q1 | alks |
Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
|
371936000 | |
| CY2020Q1 | alks |
Marketable Investments Securities Unrealized Gain Loss
MarketableInvestmentsSecuritiesUnrealizedGainLoss
|
2717000 | |
| CY2020Q1 | alks |
Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
|
980000 | |
| CY2020Q1 | alks |
Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
|
2000 | |
| CY2020Q1 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
373671000 | |
| CY2019Q4 | alks |
Short Term Investment Amortized Cost
ShortTermInvestmentAmortizedCost
|
329862000 | |
| CY2019Q4 | alks |
Short Term Investment Securities Unrealized Gain Loss
ShortTermInvestmentSecuritiesUnrealizedGainLoss
|
1358000 | |
| CY2019Q4 | alks |
Short Term Investment Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
ShortTermInvestmentSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
|
11000 | |
| CY2019Q4 | alks |
Short Term Investment Securities Continuous Unrealized Loss Position More Than12 Months Aggregate Losses
ShortTermInvestmentSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAggregateLosses
|
1000 | |
| CY2019Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
331208000 | |
| CY2019Q4 | alks |
Long Term Investment Amortized Cost
LongTermInvestmentAmortizedCost
|
79363000 | |
| CY2019Q4 | alks |
Long Term Investment Securities Unrealized Gain Loss
LongTermInvestmentSecuritiesUnrealizedGainLoss
|
102000 | |
| CY2019Q4 | alks |
Long Term Investment Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
|
67000 | |
| CY2019Q4 | alks |
Long Term Investment Securities Continuous Unrealized Loss Position More Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAggregateLosses
|
7000 | |
| CY2019Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
79391000 | |
| CY2019Q4 | alks |
Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
|
409225000 | |
| CY2019Q4 | alks |
Marketable Investments Securities Unrealized Gain Loss
MarketableInvestmentsSecuritiesUnrealizedGainLoss
|
1460000 | |
| CY2019Q4 | alks |
Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
|
78000 | |
| CY2019Q4 | alks |
Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
|
8000 | |
| CY2019Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
410599000 | |
| CY2020Q1 | alks |
Marketable Securities Realized Gain
MarketableSecuritiesRealizedGain
|
9000 | |
| CY2020Q1 | us-gaap |
Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
|
3545000 | |
| CY2020Q1 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
3487000 | |
| CY2020Q1 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
3545000 | |
| CY2020Q1 | alks |
Fair Value Recurring Basis Assets Or Liabilities Transfers Between Levels
FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevels
|
0 | |
| CY2020Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
41153000 | |
| CY2020Q1 | us-gaap |
Business Combination Contingent Consideration Asset Noncurrent
BusinessCombinationContingentConsiderationAssetNoncurrent
|
39200000 | |
| CY2019Q4 | us-gaap |
Business Combination Contingent Consideration Asset Noncurrent
BusinessCombinationContingentConsiderationAssetNoncurrent
|
32400000 | |
| CY2020Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
|
6800000 | |
| CY2019Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
|
-22600000 | |
| CY2020Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
35578000 | |
| CY2019Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
34577000 | |
| CY2020Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
51337000 | |
| CY2019Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
54061000 | |
| CY2020Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
22399000 | |
| CY2019Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
13165000 | |
| CY2020Q1 | us-gaap |
Inventory Net
InventoryNet
|
109314000 | |
| CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
101803000 | |
| CY2020Q1 | alks |
Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider
InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider
|
19000000.0 | |
| CY2019Q4 | alks |
Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider
InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider
|
7600000 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
690405000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
679213000 | |
| CY2020Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
327866000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
317045000 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
362539000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
362168000 | |
| CY2020Q1 | us-gaap |
Goodwill Gross
GoodwillGross
|
92873000 | |
| CY2020Q1 | us-gaap |
Goodwill
Goodwill
|
92873000 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
582750000 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
441835000 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
140915000 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
40000000.0 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
40000000.0 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
35000000.0 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
35000000.0 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
1000000.0 | |
| CY2018Q1 | us-gaap |
Area Of Real Estate Property
AreaOfRealEstateProperty
|
220000 | |
| CY2018Q1 | alks |
Lease Agreement Commencement Date
LeaseAgreementCommencementDate
|
2020-01-20 | |
| CY2018Q1 | alks |
Lease Expiration Year
LeaseExpirationYear
|
2035 | |
| CY2018Q1 | alks |
Operating Lease Provision For Extension Of Term
OperatingLeaseProvisionForExtensionOfTerm
|
P10Y | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0555 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P14Y2M12D | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2400000 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2300000 | |
| CY2020Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
3900000 | |
| CY2019Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
2100000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
13690000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
9053000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
12743000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2727000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
500000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
10770000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
509000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
10897000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
520000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
116520000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
2579000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
175265000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
15888000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
57664000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2080000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
117601000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
13808000 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
54261000 | |
| CY2020Q1 | us-gaap |
Due To Employees Current
DueToEmployeesCurrent
|
51536000 | |
| CY2019Q4 | us-gaap |
Due To Employees Current
DueToEmployeesCurrent
|
72072000 | |
| CY2020Q1 | alks |
Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
|
154284000 | |
| CY2019Q4 | alks |
Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
|
153902000 | |
| CY2020Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
64595000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
92802000 | |
| CY2020Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
313592000 | |
| CY2019Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
373037000 | |
| CY2020Q1 | us-gaap |
Restructuring And Related Activities Description
RestructuringAndRelatedActivitiesDescription
|
The Restructuring included a reduction in headcount of approximately 160 employees across the Company. The Company recorded a charge of $13.4 million in the fourth quarter of 2019 as a result of the Restructuring, which consisted of one-time termination benefits for employee severance, benefits and related costs, all of which are expected to result in cash expenditures and substantially all of which will be paid out over the next 12 months. | |
| CY2019Q4 | us-gaap |
Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
|
160 | |
| CY2019Q4 | us-gaap |
Restructuring Charges
RestructuringCharges
|
13400000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
19813000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
24616000 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
19245 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
14754 | |
| CY2020Q1 | alks |
Restructuring And Related Activities Initiation Month And Year
RestructuringAndRelatedActivitiesInitiationMonthAndYear
|
October 2019 | |
| CY2019Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
9201000 | |
| CY2020Q1 | alks |
Payments For Restructuring Severance
PaymentsForRestructuringSeverance
|
3759000 | |
| CY2020Q1 | alks |
Payments For Restructuring Outplacement Services
PaymentsForRestructuringOutplacementServices
|
62000 | |
| CY2020Q1 | alks |
Payments For Restructuring Benefits
PaymentsForRestructuringBenefits
|
767000 | |
| CY2020Q1 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
4613000 | |
| CY2020Q1 | us-gaap |
Loss Contingency Accrual Provision
LossContingencyAccrualProvision
|
0 | |
| CY2020Q1 | alks |
Number Of Product Liability Lawsuits
NumberOfProductLiabilityLawsuits
|
2 |
